These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 10630739

  • 1. Comparison of doxorubicin- and MEN 10755-induced long-term progressive cardiotoxicity in the rat.
    Cirillo R, Sacco G, Venturella S, Brightwell J, Giachetti A, Manzini S.
    J Cardiovasc Pharmacol; 2000 Jan; 35(1):100-8. PubMed ID: 10630739
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Continuous electrocardiogram reveals differences in the short-term cardiotoxic response of Wistar-Kyoto and spontaneously hypertensive rats to doxorubicin.
    Hazari MS, Haykal-Coates N, Winsett DW, Costa DL, Farraj AK.
    Toxicol Sci; 2009 Jul; 110(1):224-34. PubMed ID: 19407338
    [Abstract] [Full Text] [Related]

  • 5. The rat model in the comparative evaluation of anthracyclines cardiotoxicity.
    Lanza E, Rozza A, Favalli L, Monti E, Poggi P, Villani F.
    Tumori; 1989 Dec 31; 75(6):533-6. PubMed ID: 2617699
    [Abstract] [Full Text] [Related]

  • 6. Comparison of cardiotoxicity of two anthracenediones and doxorubicin in rats.
    Zbinden G, Beilstein AK.
    Toxicol Lett; 1982 May 31; 11(3-4):289-97. PubMed ID: 7101322
    [Abstract] [Full Text] [Related]

  • 7. Cardioprotective effects of zofenopril, a new angiotensin-converting enzyme inhibitor, on doxorubicin-induced cardiotoxicity in the rat.
    Sacco G, Bigioni M, Evangelista S, Goso C, Manzini S, Maggi CA.
    Eur J Pharmacol; 2001 Feb 23; 414(1):71-8. PubMed ID: 11230997
    [Abstract] [Full Text] [Related]

  • 8. Morphine is protective against doxorubicin-induced cardiotoxicity in rat.
    Kelishomi RB, Ejtemaeemehr S, Tavangar SM, Rahimian R, Mobarakeh JI, Dehpour AR.
    Toxicology; 2008 Jan 14; 243(1-2):96-104. PubMed ID: 17988779
    [Abstract] [Full Text] [Related]

  • 9. Dissociation between in vitro cytotoxicity and in vivo cardiotoxicity of two new anthracyclines: 3'-deamino-3'-(2-methoxy-4-morpholinyl)doxorubicin and 4'-deoxy-4'-iodo-doxorubicin.
    Pinna A, Agen C, Di Paolo A, Innocenti F, Nardini D, Danesi R, Del Tacca M.
    J Environ Pathol Toxicol Oncol; 1994 Jan 14; 13(1):25-31. PubMed ID: 7823290
    [Abstract] [Full Text] [Related]

  • 10. Doxorubicin mediated cardiotoxicity in rats: protective role of felodipine on cardiac indices.
    Gandhi H, Patel VB, Mistry N, Patni N, Nandania J, Balaraman R.
    Environ Toxicol Pharmacol; 2013 Nov 14; 36(3):787-95. PubMed ID: 23958971
    [Abstract] [Full Text] [Related]

  • 11. Effect of trimetazidine on early and delayed doxorubicin myocardial toxicity.
    Perletti G, Monti E, Paracchini L, Piccinini F.
    Arch Int Pharmacodyn Ther; 1989 Nov 14; 302():280-9. PubMed ID: 2636823
    [Abstract] [Full Text] [Related]

  • 12. Anthracycline metabolism and toxicity in human myocardium: comparisons between doxorubicin, epirubicin, and a novel disaccharide analogue with a reduced level of formation and [4Fe-4S] reactivity of its secondary alcohol metabolite.
    Minotti G, Licata S, Saponiero A, Menna P, Calafiore AM, Di Giammarco G, Liberi G, Animati F, Cipollone A, Manzini S, Maggi CA.
    Chem Res Toxicol; 2000 Dec 14; 13(12):1336-41. PubMed ID: 11123976
    [Abstract] [Full Text] [Related]

  • 13. Doxorubicin-induced late cardiotoxicity: delayed impairment of Ca2+-handling mechanisms in the sarcoplasmic reticulum in the rat.
    Chugun A, Temma K, Oyamada T, Suzuki N, Kamiya Y, Hara Y, Sasaki T, Kondo H, Akera T.
    Can J Physiol Pharmacol; 2000 Apr 14; 78(4):329-38. PubMed ID: 10772060
    [Abstract] [Full Text] [Related]

  • 14. Doxorubicin (adriamycin)-induced cardiotoxicity in turkey poults: an animal model.
    Czarnecki CM.
    Comp Biochem Physiol C Comp Pharmacol Toxicol; 1986 Apr 14; 83(1):53-60. PubMed ID: 2869907
    [Abstract] [Full Text] [Related]

  • 15. Remodeling of ventricular repolarization in a chronic doxorubicin cardiotoxicity rat model.
    Kharin S, Krandycheva V, Tsvetkova A, Strelkova M, Shmakov D.
    Fundam Clin Pharmacol; 2013 Aug 14; 27(4):364-72. PubMed ID: 22429163
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of cardiotoxicity of a new anthracycline derivative: 4'-deoxy-4'-iodo-doxorubicin.
    Villani F, Galimberti M, Lanza E, Rozza A, Favalli L, Poggi P.
    Invest New Drugs; 1988 Sep 14; 6(3):173-8. PubMed ID: 3192383
    [Abstract] [Full Text] [Related]

  • 17. Comparison of cardiotoxicity of pirarubicin, epirubicin and doxorubicin in the rat.
    Hirano S, Wakazono K, Agata N, Iguchi H, Tone H.
    Drugs Exp Clin Res; 1994 Sep 14; 20(4):153-60. PubMed ID: 7813387
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of anthracycline cardiotoxicity with the model of isolated, perfused rat heart: comparison of new analogues versus doxorubicin.
    Pouna P, Bonoron-Adèle S, Gouverneur G, Tariosse L, Besse P, Robert J.
    Cancer Chemother Pharmacol; 1995 Sep 14; 35(3):257-61. PubMed ID: 7805186
    [Abstract] [Full Text] [Related]

  • 19. Effect of ICRF-187 pretreatment against doxorubicin-induced delayed cardiotoxicity in the rat.
    Villani F, Galimberti M, Monti E, Cova D, Lanza E, Rozza-Dionigi A, Favalli L, Poggi P.
    Toxicol Appl Pharmacol; 1990 Feb 14; 102(2):292-9. PubMed ID: 2105541
    [Abstract] [Full Text] [Related]

  • 20. Preclinical assessment of the cardiotoxic potential of anthracycline antibiotics: N-L-leucyl-doxorubicin.
    Zbinden G, DeCampeenere D, Baurain R.
    Arch Toxicol Suppl; 1991 Feb 14; 14():107-17. PubMed ID: 1805716
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.